Accessibility Menu
Quoin Pharmaceuticals logo

Quoin Pharmaceuticals(NASDAQ) QNRX

Market Cap$8.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-34%
1 Month-6%
$4.03
-5.73%
-0.25Today
After hours$4.40+$0.37 (+9.28%)
Quoin Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 4.452026-07-31
Quoin Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.97%USD 4.282026-07-24
1 month-5.52%USD 4.712026-07-01
3 month-28.34%USD 6.212026-05-01
Year to date-69.16%USD 14.432025-12-31
1 year-33.58%USD 6.702025-07-31
3 year-98.38%USD 275.452023-08-01
5 year-100%USD 89,670.002021-07-30
Since inception-99.99%USD 61,110.092021-10-29

Quoin Pharmaceuticals Financials at a Glance

Market Cap

$8.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$16.98M

EPS (TTM)

-$236.73

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.33 (Average)

Price

$4.03

Volume

17,706.208

Open

$4.37

Previous Close

$4.45

Daily Range

$4.25 - $4.49

52-Week Range

$3.25 - $41.80

Estimated Earnings Date

Aug 6, 2026

QNRX News

Foolcom-Featured.png

Quoin (QNRX) Q2 Loss Beats Estimates

Motley Fool Markets TeamAug 8, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quoin Pharmaceuticals

Quoin develops medicines for people with rare skin diseases. Its main products aim to help those with few or no treatment options. These therapies are designed to improve daily life for patients with severe genetic conditions.

Products and Services

  • QRX003 Lotion: Topical treatment for Netherton Syndrome, a rare inherited skin disorder (0% of revenue; pre-commercial).
  • QRX004 Therapy: Developed for dystrophic epidermolysis bullosa, a rare skin disease (0% of revenue).
  • QRX006 Candidate: Targets other rare genetic skin diseases (0% of revenue).
  • QRX008 Small Molecule: Early-stage option for scleroderma, a chronic connective tissue disease (0% of revenue).
  • QRX009 Topical Rapamycin: For rare and orphan diseases, developed with university partners (0% of revenue).

Growth and Expansion

  • Formed research partnerships with Queensland University of Technology (Australia) and University College Cork (Ireland) in 2024-2025.
  • Expanded clinical trials to the US, UK, Spain, France, Netherlands, Ireland, Austria, and New Zealand by 2025.
  • Signed commercial distribution agreements covering 61 countries outside the US, Western Europe, and Japan by 2025.
  • Secured regulatory designations in the US and Europe for lead product QRX003 between 2023 and 2025.
  • Raised capital through private placements and offerings in 2024 and 2025 to fund development.

What Makes Quoin Stand Out

Quoin targets rare diseases with no approved treatments, focusing on severe skin disorders. The company operates globally through research and commercial partnerships. Its strategy centers on late-stage clinical development and regulatory designations to speed up approval.

Five Things You Need to Know

  • No revenue reported for 2023, 2024, or 2025; company is pre-commercial.
  • Net loss was $15.8 million in 2025, up 76% from 2024.
  • R&D expenses rose 172% to $9.8 million in 2025.
  • Cash and investments totaled $18.7 million as of December 31, 2025.
  • Management disclosed substantial doubt about continuing as a going concern in 2025.

Bottom Line

Quoin remains focused on developing treatments for rare skin diseases. The company faces ongoing financial challenges as it works toward commercializing its pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Michael Myers, PhD

Website

www.quoinpharma.com

Headquarters

Ashburn, VA 20148-7349, US

QNRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-292.33%

Return on Capital

-124.17%

Return on Assets

-108.18%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.96M

Volume

17.71K

Avg. Volume

237.78K

Financials (TTM)

Gross Profit

-$24.93K

Operating Income

-$17.45M

EBITDA

-$16.88M

Operating Cash Flow

-$15.86M

Capital Expenditure

$4.00

Free Cash Flow

-$15.86M

Cash & ST Invst.

$3.12M

Total Debt

$0.00

Quoin Pharmaceuticals Performance Analysis

Quoin Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Quoin Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Quoin Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -11.42-99.5%
20232023-12-31USD -11,781.48103032.8%
20242024-12-31USD -2,352.81-80.0%
20252025-12-31USD -10.63-99.5%
Quoin Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-303.4%
Q32025-09-30-6.8%
Q42025-12-3156.5%
Q12026-03-3139.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$24.93K

N/A

Gross Margin

0.00%

N/A

Market Cap

$8.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.18M

N/A

Employees

4

N/A

Net Income

-$4.98M

-30.7%

EBITDA

-$4.96M

-30.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.12M

-73.0%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.08%

N/A

Return on Invested Capital

-1.69%

N/A

Free Cash Flow

-$4.87M

-87.7%

Operating Cash Flow

-$4.87M

-87.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XTLBXTL Biopharmaceuticals Ltd.
$2.86+1.45%
PLRZPolyrizon Ltd.
$10.59-5.87%
TCRTAlaunos Therapeutics, Inc.
$1.91+1.33%
RADXRadiopharm Theranostics Limited
$3.11-1.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About QNRX

What is the current price of Quoin Pharmaceuticals?

Quoin Pharmaceuticals is trading at $4.45 per share.

What is the 52-week range for Quoin Pharmaceuticals?

Over the past 52 weeks, Quoin Pharmaceuticals has traded between $3.25 and $41.80.

How much debt does Quoin Pharmaceuticals have?

As of the most recent reporting period, Quoin Pharmaceuticals reported total debt of $0.00.

How much cash does Quoin Pharmaceuticals have on hand?

Quoin Pharmaceuticals reported $3.12M in cash and cash equivalents in its most recent financial results.

What is Quoin Pharmaceuticals’s dividend yield?

Quoin Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services